Injectable PrEP and other options are in the pipeline, and that makes clinical trials more complicated
Oct. 14, 2016
| By Mary Engel / Fred Hutch News Service
An injectable form of PrEP and other options are in the pipeline as the HIV field enters a new era of prevention. But such advances, as welcome as they are, come with a twist: They complicate the task of designing the clinical trials needed to test additional tools. Fred Hutch's Dr. Deborah Donnell explains.
SCHARP data shows longer nevirapine treatment reduces infection by half for babies with HIV-infected mothers, 75 percent for infants of untreated moms
March 14, 2011
Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of HIV transmission to the infants at age 6 months compared with giving infants the drug daily for six weeks, according to preliminary clinical trial data presented March 2 at the Retroviruses and Opportunistic Infections conference in Boston.
Antiretroviral therapy associated with 92 percent decreased risk of HIV transmission among HIV-1 discordant couples in large, multinational study
June 1, 2010
Research led by Dr. Deborah Donnell of the Vaccine and Infectious Disease Institute at the Fred Hutchinson Cancer Research Center has found that treating HIV-infected persons with antiretroviral therapy (ART) reduces HIV transmission to their sexual partners by more than 90 percent.